Royalty Pharma Announces Promotions in Finance Team in Anticipation of Next Growth Phase

Royalty Pharma is pleased to announce that Susannah Gray has been named Executive Vice President – Finance & Strategy, Terrance Coyne has been promoted to Chief Financial Officer, and Kristin Stafford has been promoted to Chief Accounting Officer. Ms. Gray and Mr. Coyne’s appointments are effective March 15, 2019, and Ms. Stafford’s promotion is effective immediately.

 

Ms. Gray joined Royalty Pharma in 2005 as Chief Financial Officer. “Since joining Royalty Pharma in 2005, Susannah has been the driving force in funding our acquisition program and has worked closely with me to set the strategic direction of Royalty Pharma. Together with the finance team, she has also created a best-in-class finance department that is well positioned to support our growth going forward. Susannah’s background and experience will make her a tremendous resource in her future role as Executive Vice President – Finance & Strategy at Royalty Pharma,” said Pablo Legorreta, Founder & Chief Executive Officer of Royalty Pharma.

 

Mr. Coyne joined Royalty Pharma in 2010 and is currently Senior Vice President – Research & Investments. Previously, Mr. Coyne was a biotechnology analyst at J.P. Morgan and Rodman & Renshaw, and began his career at Wyeth Pharmaceuticals. “Since joining Royalty Pharma in 2010, Terry has played a key role in the acquisition of over $8 billion in royalty assets and has played an important role in recent strategic planning efforts,” said Mr. Legorreta. “Terry’s deep understanding of the products in our portfolio, the life sciences industry and the biopharma investment community make him the ideal candidate to serve as Chief Financial Officer of Royalty Pharma as we plan for future growth,” Mr. Legorreta continued.

 

Ms. Stafford joined Royalty Pharma in 2016. Previously, Ms. Stafford was a Director, Capital Markets at Ernst & Young LLP in London, specializing in initial public offerings and other capital markets transactions for European life sciences companies. Ms. Stafford also previously managed the external SEC reporting for iHeartMedia and was an auditor at Deloitte.

 

Royalty Pharma is also pleased to announce three additional promotions within its finance team. Jim Rielly is promoted to Senior Vice President, Finance. Jim joined Royalty Pharma in 1999. Jim was previously the CFO of Cadus Pharmaceutical Corporation. Jim has a BSBA and is a Certified Public Accountant. Jessica Veeramachaneni is promoted to Vice President & Controller, from her current position as Controller. Jessica joined Royalty Pharma in 2011, and has a BBA in accounting and is a Certified Public Accountant. Sarah Cata is promoted to Vice President, Finance. Sarah joined Royalty Pharma in 2014. Sarah was previously an associate in the Healthcare Investment Banking group at J.P. Morgan. Sarah has a BS in finance and accounting.

 

“I am delighted to congratulate Susannah, Terry, Kristin, Jim, Jessica and Sarah on their new roles, which reflect the strength and breadth of the finance team’s capital markets, corporate finance, treasury, planning and analysis, tax, accounting, audit and risk management expertise. These internal appointments further strengthen our leadership team for the next phase of Royalty Pharma’s transformation and growth,” said Mr. Legorreta.

 

About Royalty Pharma

 

Royalty Pharma is the industry leader in acquiring royalty interests in marketed and late-stage biopharmaceutical products, with a portfolio that includes royalty interests in over 50 approved products, valued at over $16 billion. Royalty Pharma does not discover, develop, manufacture or market biopharmaceutical products. Royalty Pharma funds innovation in life sciences, indirectly, when it acquires existing royalty interests from the original innovators (academic institutions, research hospitals, foundations and inventors) or, directly, when it partners with life sciences companies to co-develop and co-fund products in human clinical trials. Royalty Pharma has assembled a portfolio that includes royalty interests in AbbVie and J&J’s Imbruvica, Biogen’s Tecfidera and Tysabri, Vertex’s Kalydeco, Orkambi and Symdeko, Pfizer and Astellas’ Xtandi, Merck’s Januvia, Gilead’s Atripla and Truvada, and Pfizer’s Lyrica, among other products. Additional company information is available at www.royaltypharma.com.

 

Royalty Pharma | RP Management LLC
Investor Relations & Public Affairs
+ 1 (212) 883-0200
ir@royaltypharma.com